CNO Financial to Preview Workplace Benefits and Medicare Growth Strategies
Key Takeaways from the Briefing
CNO Financial Group (CNO) will host a virtual investor briefing on September 1, 2026, focusing on its Workplace Benefits and Medicare businesses. This event is not an earnings call but rather a corporate presentation designed to explain the revenue models and sales strategies of these two growth pillars. A key focus will be on the performance following the shift away from fee-based workplace wellness services (completed by the first half of 2025) and the increased focus on insurance underwriting and sales.
Workplace Benefits Profitability
CNO's Workplace Benefits segment provides voluntary benefits products, including life, critical illness, accident, and hospital indemnity insurance, through its Washington National and Optavise exclusive and independent distribution networks. In 2025, new annual premium (NAP) reached a record high, increasing by 15% year-over-year, marking the 15th consecutive quarter of growth. The discontinuation of the fee-based business acquired from Web Benefits Design and DirectPath will reduce annual revenue by approximately USD 30 million but is expected to increase pre-tax earnings by approximately USD 20 million, reflecting a strategic decision to prioritize margins over revenue. The briefing will highlight the speed at which these profit improvements are realized and the productivity differentiation in the workplace supplemental insurance market, where CNO competes with Aflac (AFL), Unum Group (UNM), and MetLife (MET).
Medicare Growth Engine
Through Bankers Life, CNO underwrites its own Medicare Supplement plans and distributes over 20 third-party Medicare Advantage plans through myHealthPolicy.com and its distribution network. In the first quarter of 2026, total Medicare sales increased by 24%, and Medicare Supplement NAP increased by 53%, demonstrating the company's ability to capture consumer demand shifting from Medicare Advantage to supplemental insurance. With approximately 68 million Americans covered and USD 1.118 trillion in spending in 2024, the U.S. Medicare market is substantial. CNO's strength lies in its ability to offer multiple products through its distribution network, allowing it to compete with UnitedHealth Group (UNH), Humana (HUM), and CVS Health (CVS) in Medicare Advantage, as well as with companies like Mutual of Omaha in the supplemental insurance market.
Investment Considerations
In 2025, CNO reported revenue of USD 4.5 billion, net income of USD 229.3 million, and total assets of USD 38.8 billion. Therefore, this briefing will serve as an opportunity to assess whether the company can translate Workplace Benefits NAP, Medicare Supplement sales, policy retention rates, and agent productivity into improved operating income. Medicare products serve as an entry point for building long-term relationships with senior customers and cross-selling annuity, life insurance, and asset management products, making new business acquisition even more valuable. The presentation of specific medium-term goals or paths to improved return on capital would serve as a catalyst for quantifying the success of the business restructuring, although the briefing itself is not related to regulatory approvals or financial transactions.
In the short term, the key focus is whether the annual revenue decrease of USD 30 million and the pre-tax income improvement of USD 20 million resulting from the discontinuation of the Workplace Benefits fee-based business will translate into actual margin improvements. With Medicare Supplement NAP increasing by 53% in the first quarter of 2026, the Medicare market, with approximately 68 million beneficiaries and USD 1.118 trillion in annual spending, provides CNO with opportunities to expand its customer base and cross-selling capabilities. In the medium to long term, CNO's competitive advantage depends on agent productivity and retention rates in the face of competition from UnitedHealth Group (UNH) and Humana (HUM) in Medicare Advantage, Mutual of Omaha in supplemental insurance, and Aflac (AFL) and Unum Group (UNM) in workplace insurance. As this is a business briefing rather than a clinical or pharmaceutical event, the basis for a revaluation will be the specificity of the new business annual premium, pre-tax income, and return on capital targets.
Source: PR Newswire Biotech (rss_filter)